STERO Biotechs Secures Patent of CBD as Steroid Sparing Treatment, Breakthrough Will Potentially Allow Significant Dosage Reduction
BNEI BRAK, Israel, Aug. 29, 2018 /PRNewswire/ -- STERO Biotechs Ltd., has received a notice of allowance and will be granted an official U.S. patent on October 2018, covering over 100 Autoimmune & chronic inflammatory diseases. The patent is for steroid sparing Cannabidiol (CBD)-based treatment that has the potential of minimizing the devastating and sometimes lethal effects of steroids, an essential therapy in many diseases. Clinical trials will begin on Q4 2018 on the first indication with more indications planned in the pipeline.
There is currently an urgent clinical unmet need to lower the dosage and time of steroids administration. STERO has discovered that CBD will allow physicians to prescribe a lower dose of steroids while retaining their therapeutic effect and, by extension, lowering unwanted side effects. The product will also bring relief to those who are currently resistant to steroid treatment alone, known as steroid refractory.
Although steroids are one of the most commonly used treatments for a multitude of conditions, they are well known to cause a large number of mild to severe adverse effects, especially in cases of high dosage or long-term use. In a recent literature review, the most commonly reported adverse effects from long-term exposure were hypertension, cataract, sleep disturbances, cardiac conditions, fractures or osteoporosis, nausea, vomiting, and other gastrointestinal and metabolic issues such as hyperglycemia, weight gain and type 2 diabetes.
"The effect of CBD on steroids will have a significant impact in the medical community. Physicians are now actively reducing or avoiding steroids due to their toxicity and we hope to provide patients with the same broad range of products to treat countless conditions, without the harm associated with traditional steroid use," said Dr. Sari Prutchi Sagiv, Senior Scientific Adviser of STERO Biotechs.
STERO Biotechs Ltd., is a company to watch as it brings a game-changing medical treatment to market. Potential investors, M&A and potential research partners can sign up here for updates.
About STERO Biotechs, Ltd.
STERO Biotechs Ltd., founded in 2017 and headquartered in Israel, is a clinical stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy. STERO has secured a U.S. patent and is planning to commence clinical trials in Q4 2018 on the first indication while having more in the pipeline.
STERO has established an active partnership with one of its shareholders - MOR Research Applications, the tech transfer company of CLALIT HEALTH SERVICES. CLALIT is the is the largest HMO in Israel, with over 4.5 million members. CLALIT operates 14 full scale hospitals specializing in all fields of medicine, as well as over 2000 community clinics with over 9000 physicians. The MOR-STERO partnership allows the company to reach vast numbers of patients and data.
For further information contact [email protected] or call +972-3-617-6173.
SOURCE STERO Biotechs Ltd.
Share this article